Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)‘s stock had its “ourperform” rating reissued by Wedbush in a research report issued to clients and investors on Monday. They presently have a $39.00 price target on the biopharmaceutical company’s stock. Wedbush’s price target indicates a potential upside of 148.57% from the company’s current price.

Several other equities analysts also recently issued reports on the stock. BidaskClub downgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Cowen and Company reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, August 1st. Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. ValuEngine raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Finally, HC Wainwright set a $27.00 price target on shares of Lexicon Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, May 3rd. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. Lexicon Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $27.00.

Lexicon Pharmaceuticals (NASDAQ:LXRX) traded down 0.89% on Monday, reaching $15.55. 151,692 shares of the company’s stock traded hands. The firm’s 50-day moving average is $16.60 and its 200 day moving average is $15.38. The stock’s market capitalization is $1.64 billion. Lexicon Pharmaceuticals has a 52-week low of $13.41 and a 52-week high of $19.62.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.12. Lexicon Pharmaceuticals had a negative net margin of 170.63% and a negative return on equity of 94.87%. The firm had revenue of $12 million during the quarter, compared to the consensus estimate of $18.34 million. During the same period last year, the firm posted ($0.37) EPS. The firm’s quarterly revenue was down 40.3% on a year-over-year basis. Analysts forecast that Lexicon Pharmaceuticals will post ($1.49) EPS for the current year.

WARNING: This news story was published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/07/wedbush-reaffirms-ourperform-rating-for-lexicon-pharmaceuticals-inc-nasdaqlxrx.html.

Institutional investors have recently made changes to their positions in the company. First Mercantile Trust Co. increased its position in shares of Lexicon Pharmaceuticals by 9.2% in the second quarter. First Mercantile Trust Co. now owns 10,700 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 900 shares in the last quarter. Alambic Investment Management L.P. bought a new position in shares of Lexicon Pharmaceuticals during the second quarter worth $165,000. C WorldWide Group Holding A S increased its position in shares of Lexicon Pharmaceuticals by 2.5% in the first quarter. C WorldWide Group Holding A S now owns 11,677 shares of the biopharmaceutical company’s stock worth $167,000 after buying an additional 280 shares in the last quarter. BlackRock Group LTD increased its position in shares of Lexicon Pharmaceuticals by 56.9% in the first quarter. BlackRock Group LTD now owns 14,217 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 5,158 shares in the last quarter. Finally, A.R.T. Advisors LLC bought a new position in shares of Lexicon Pharmaceuticals during the first quarter worth $174,000.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.